HEART FAILURE AND URATE-LOWERING THERAPY: CLINICAL ASPECTS

Abstract

Heart failure (HF) is a widespread disease that represents a global problem. In this regard, studies aimed at finding approaches that reduce the risks of adverse events associated with HF are relevant. Experts agree that there is an urgent need for cost - effective prognostic biomarkers in heart failure available in routine clinical practice. This review focuses on uric acid, which reflects the state of purine metabolism, which is impaired in cardiovascular pathology. Hyperuricemia is not only associated with an increased incidence of HF, but is also considered an independent predictor of mortality in acute and chronic HF. Xanthine oxidase, which regulates serum uric acid levels, may serve as a therapeutic target in HF. The review presents data from a number of clinical studies and meta - analyses on the use of urate - lowering drugs in patients with cardiovascular pathology, including heart failure.